BS_RGPSEMHC
Posterior Fossa Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Posterior Fossa Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Posterior Fossa Ependymoma
- overall_survival_months
- 51.57687253613666
- age_years
- 5.984
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.631
- INTERFERON_ALPHA_RESPONSE+0.626
- IL6_JAK_STAT3_SIGNALING+0.593
- ALLOGRAFT_REJECTION+0.555
- INFLAMMATORY_RESPONSE+0.520
- TNFA_SIGNALING_VIA_NFKB+0.474
- ANGIOGENESIS+0.458
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.424
- COAGULATION+0.406
- COMPLEMENT+0.382
Top 10 suppressed
- MYC_TARGETS_V2-0.496
- MYC_TARGETS_V1-0.450
- OXIDATIVE_PHOSPHORYLATION-0.440
- G2M_CHECKPOINT-0.439
- E2F_TARGETS-0.433
- UNFOLDED_PROTEIN_RESPONSE-0.243
- DNA_REPAIR-0.242
- MTORC1_SIGNALING-0.239
- CHOLESTEROL_HOMEOSTASIS-0.230
- MITOTIC_SPINDLE-0.212
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-L9-A743-01A-43R-A39D-07 | — | cohortA1 | 0.935 |
| 2 | SRR5088860 | — | — | 0.931 |
| 3 | BS_JHGW42S6 | EPN | Posterior Fossa EPN | 0.929 |
| 4 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.927 |
| 5 | SRR22247245 | — | cohortMD2 | 0.922 |
| 6 | BS_1RXZ3BP7 | low-grade glioma | — | 0.920 |
| 7 | TCGA-22-4596-01A-01R-1201-07 | — | cohortA1 | 0.917 |
| 8 | BS_JHGW42S6 | Posterior Fossa Ependymoma | — | 0.915 |
| 9 | BS_3H71BH6Q | Ganglioglioma | — | 0.914 |
| 10 | BS_02NZT8CE | low-grade glioma | — | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.631 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.626 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.593 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.555 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.474 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.458 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.424 | Inavolisib | — uncovered |
| COAGULATION | 0.406 | Binimetinib | — uncovered |
| COMPLEMENT | 0.382 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.274 | Inavolisib | — uncovered |
| APOPTOSIS | 0.263 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.262 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.251 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.213 | Inavolisib | — uncovered |
| HYPOXIA | 0.165 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.151 | Idelalisib | — uncovered |
| MYOGENESIS | 0.146 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.132 | Idelalisib | — uncovered |